Asian Growth Companies With High Insider Ownership In June 2025
Reviewed by Simply Wall St
As of June 2025, the Asian markets are navigating a complex landscape marked by geopolitical tensions and evolving trade dynamics, with recent developments between China and the U.S. offering some optimism amid broader deflationary pressures in China. In this context, growth companies with high insider ownership can be particularly appealing to investors seeking stability and alignment of interests during uncertain times.
Top 10 Growth Companies With High Insider Ownership In Asia
Name | Insider Ownership | Earnings Growth |
Zhejiang Leapmotor Technology (SEHK:9863) | 15.6% | 59.9% |
Vuno (KOSDAQ:A338220) | 15.6% | 109.8% |
Suzhou Sunmun Technology (SZSE:300522) | 35.4% | 77.7% |
Shanghai Huace Navigation Technology (SZSE:300627) | 24.3% | 23.5% |
Schooinc (TSE:264A) | 30.6% | 68.9% |
Samyang Foods (KOSE:A003230) | 11.7% | 24.3% |
Oscotec (KOSDAQ:A039200) | 21.1% | 94.4% |
M31 Technology (TPEX:6643) | 30.8% | 63.4% |
Laopu Gold (SEHK:6181) | 35.5% | 40.3% |
Fulin Precision (SZSE:300432) | 13.6% | 43% |
Let's review some notable picks from our screened stocks.
Ocumension Therapeutics (SEHK:1477)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ocumension Therapeutics is an ophthalmic pharmaceutical platform company operating in the People's Republic of China, with a market cap of HK$8.22 billion.
Operations: The company's revenue segment focuses on the discovery, development, and commercialization of ophthalmic therapies, generating CN¥417.31 million.
Insider Ownership: 20.6%
Revenue Growth Forecast: 30.4% p.a.
Ocumension Therapeutics, with substantial insider ownership, is poised for significant growth. Its revenue is expected to grow at 30.4% annually, outpacing the Hong Kong market's 8.2%. Despite recent shareholder dilution and a volatile share price, earnings are forecasted to increase by over 100% per year. The company recently received approval for its OT-703 product in China’s Boao Lecheng zone and continues to expand its presence in Asia through strategic licensing agreements.
- Click to explore a detailed breakdown of our findings in Ocumension Therapeutics' earnings growth report.
- The valuation report we've compiled suggests that Ocumension Therapeutics' current price could be inflated.
Henan Shijia Photons Technology (SHSE:688313)
Simply Wall St Growth Rating: ★★★★★★
Overview: Henan Shijia Photons Technology Co., Ltd. (SHSE:688313) operates in the photonics industry with a market cap of CN¥16.67 billion.
Operations: Henan Shijia Photons Technology generates revenue primarily from its Optical Networking Equipments segment, which amounts to CN¥1.31 billion.
Insider Ownership: 10.1%
Revenue Growth Forecast: 28.0% p.a.
Henan Shijia Photons Technology, with significant insider ownership, is experiencing robust growth. The company's revenue and earnings are forecasted to grow at 28% and 40.2% annually, respectively, surpassing the broader Chinese market's growth rates. Recent financial results showed a dramatic increase in net income from CNY 8.44 million to CNY 93.19 million year-over-year for Q1 2025. Despite a highly volatile share price recently, its return on equity is expected to reach high levels in three years.
- Navigate through the intricacies of Henan Shijia Photons Technology with our comprehensive analyst estimates report here.
- The analysis detailed in our Henan Shijia Photons Technology valuation report hints at an inflated share price compared to its estimated value.
Luoyang Xinqianglian Slewing Bearing (SZSE:300850)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Luoyang Xinqianglian Slewing Bearing Co., Ltd. operates in the manufacturing sector, specializing in the production of slewing bearings, with a market cap of CN¥13.65 billion.
Operations: Revenue Segments: The company generates its income primarily from the manufacturing of slewing bearings, contributing significantly to its financial performance.
Insider Ownership: 34.2%
Revenue Growth Forecast: 18.3% p.a.
Luoyang Xinqianglian Slewing Bearing demonstrates strong growth potential, with earnings forecasted to grow at 29.61% annually, outpacing the Chinese market's 23.2%. Despite a recent decrease in dividends and a decline in net income from CNY 374.84 million to CNY 65.38 million for the full year, Q1 2025 results showed significant recovery with net income rising to CNY 170.48 million from a loss of CNY 51.77 million year-over-year.
- Unlock comprehensive insights into our analysis of Luoyang Xinqianglian Slewing Bearing stock in this growth report.
- Our comprehensive valuation report raises the possibility that Luoyang Xinqianglian Slewing Bearing is priced higher than what may be justified by its financials.
Summing It All Up
- Access the full spectrum of 609 Fast Growing Asian Companies With High Insider Ownership by clicking on this link.
- Searching for a Fresh Perspective? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:1477
Ocumension Therapeutics
Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China.
Flawless balance sheet with high growth potential.
Market Insights
Community Narratives
